These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15855303)

  • 1. Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency.
    Kilic SS
    J Trop Pediatr; 2005 Jun; 51(3):194-5. PubMed ID: 15855303
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept in the treatment of macrophage activation syndrome.
    Prahalad S; Bove KE; Dickens D; Lovell DJ; Grom AA
    J Rheumatol; 2001 Sep; 28(9):2120-4. PubMed ID: 11550985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab.
    Kuek A; Hazleman BL; Gaston JH; Ostör AJ
    Rheumatology (Oxford); 2006 Nov; 45(11):1448-9. PubMed ID: 16920752
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
    Narváez J; Díaz-Torné C; Juanola X; Geli C; Llobet JM; Nolla JM; Díaz-López C
    Ann Rheum Dis; 2009 Apr; 68(4):607-8. PubMed ID: 19286909
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of juvenile idiopathic arthritis].
    Yokota S; Umebayashi H; Katakura S; Imagawa T; Mori M
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():453-8. PubMed ID: 15799398
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on biologics in juvenile idiopathic arthritis.
    Ilowite NT
    Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome in juvenile rheumatoid arthritis in India.
    Aggarwal A; Agarwal V; Danda D; Misra R
    Indian Pediatr; 2004 Feb; 41(2):180-4. PubMed ID: 15004305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M; Tarò M; Magni-Manzoni S; Pistorio A; Traverso F; Viola S; Magnani A; Gasparini C; Martini A; Ravelli A
    Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile idiopathic arthritis: some progress but still many uncertainties.
    Prescrire Int; 2007 Aug; 16(90):168. PubMed ID: 17724846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early juvenile idiopathic arthritis.
    Marzan KA; Shaham B
    Rheum Dis Clin North Am; 2012 May; 38(2):355-72. PubMed ID: 22819089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab in juvenile rheumatoid arthritis.
    de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
    N Engl J Med; 2008 Dec; 359(23):2496; author reply 2496-7. PubMed ID: 19065700
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?
    de Benedetti F; Martini A
    Arthritis Rheum; 2005 Mar; 52(3):687-93. PubMed ID: 15751082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.